The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1258
Aliskiren (Tekturna) for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Aliskiren (ah LIS ker in; Tekturna – Novartis), the first direct renin inhibitor, has been approved by the FDA for treatment of hypertension. It is indicated for oral use either as monotherapy or in combination with other antihypertensive agents.

MECHANISM OF ACTION — Renin catalyzes the cleavage of angiotensinogen to form angiotensin I, the first and rate-limiting step of the renin-angiotensinaldosterone system (RAAS). Aliskiren binds renin, leading to reduced levels of angiotensin I, angiotensin II and aldosterone.

All drugs that inhibit RAAS, including aliskiren, can cause a compensatory increase in plasma renin concentrations (PRC), but unlike angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), aliskiren does not appear to increase plasma renin activity (PRA) because it binds renin with high affinity in plasma.1,2 In one pharmacokinetic ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Aliskiren (Tekturna) for Hypertension
Article code: 1258a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian